Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | TYMP | P19971 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SYNJ2 | O15056 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23488277 | 0.89 | XDH (0.57) | XDHTDP1MAOBTYMPKMT2A | |
| SCHEMBL23488132 | 0.87 | XDH (0.56) | XDHTDP1MAOBTYMPKMT2A | |
| SCHEMBL23488261 | 0.87 | TDP1 (0.54) | XDHTDP1MAOBTYMPKMT2A | |
| SCHEMBL23488411 | 0.87 | XDH (0.47) | XDHTDP1MAOBTYMPSYNJ2 | |
| SCHEMBL23488434 | 0.83 | XDH (0.49) | XDHTDP1TYMPKMT2AALDH1A1 | |
| SCHEMBL23488609 | 0.82 | XDH (0.48) | XDHTDP1TYMPKMT2AALDH1A1 | |
| SCHEMBL23488423 | 0.80 | XDH (0.46) | XDHTDP1MAOBTYMPSYNJ2 | |
| SCHEMBL23488267 | 0.79 | MAOB (0.47) | XDHTDP1MAOBTYMPSYNJ2 | |
| SCHEMBL20873307 | 0.78 | XDH (0.57) | XDHTDP1MAOBTYMPKMT2A | |
| SCHEMBL23488424 | 0.78 | XDH (0.49) | XDHTDP1MAOBTYMPKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | XDH 3028/4885TDP1 4093/4885MAOB 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.